VR Logo

Trevena Inc. (TRVN) download report


Healthcare | Biotechnology & Pharma Research

Trevena Inc. (TRVN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.

IPO Date: 31-Jan-2014

Pres, CEO & Director: Ms. Carrie L. Bourdow

Sr. VP & CFO: Mr. Barry Shin

Listing: NASDAQ: TRVN

Country: United States

Headquarters: Chesterbrook, PA

Website: https://www.trevena.com

Key Facts

Market cap: $64.55 Mln

Revenue (TTM): $0.59 Mln

Earnings (TTM): $-58.14 Mln

Cash: $48.66 Mln

Total Debt: $6.91 Mln

Insider's Holding: 1.35%

Liquidity: Low

52 Week range: $0.19 - 1.72

Shares outstanding: 165,520,000

10 Years Aggregate:

  • CFO: $-402.34 Mln
  • EBITDA: $-386.47 Mln
  • Net Profit: $-399.05 Mln

Stock Performance

Time Period Trevena (TRVN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-33.10-8.62-18.78
1 month40.29-4.54-8.00
3 months-29.09-10.19-13.65
1 Year-76.921.43-17.19
3 Years-27.6510.146.10
5 Years-29.8811.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Trevena (TRVN) S&P Small-Cap 600 S&P BSE Sensex
2021-72.7625.2721.99
2020154.499.5715.75
201995.5620.8614.38
2018-72.93-9.705.87
2017-72.7911.7327.91
2016-44.0024.741.95
201575.59-3.36-5.03